@article{3076650,
    title = "The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM",
    author = "Cavalier, E. and Vasikaran, S. and Bhattoa, H.P. and Heijboer, A.C. and Makris, K. and Ulmer, C.Z.",
    journal = "Clinica Chimica Acta",
    year = "2021",
    volume = "515",
    pages = "44-51",
    publisher = "Elsevier B.V.",
    issn = "0009-8981",
    doi = "10.1016/j.cca.2020.12.022",
    keywords = "parathyroid hormone;  parathyroid hormone, amino terminal sequence;  Article;  carboxy terminal sequence;  chronic kidney failure;  human;  liquid chromatography-mass spectrometry;  parathyroid hormone blood level;  priority journal;  standardization;  chronic kidney failure;  immunoassay;  standard, Humans;  Immunoassay;  Kidney Failure, Chronic;  Parathyroid Hormone;  Reference Standards;  Renal Insufficiency, Chronic",
    abstract = "Parathyroid hormone (PTH) determination is of greatest importance for patients suffering from parathyroid gland disorders and for the follow-up of bone turnover in patients suffering from chronic kidney disease (CKD). Two generations of PTH assays are simultaneously present on the market for PTH quantification. As these assays are not yet standardized, this results in a significant level of confusion in the care of CKD patients. One key objective of the IFCC Committee for Bone Metabolism is to improve this situation. In this position paper, we will highlight the current state of PTH testing and propose a pathway to ultimately overcome issues resulting from PTH assay variability. © 2020"
}